From Financial Modeling Prep: 2025-06-13 16:00:00

AIM ImmunoTech Inc. (AMEX:AIM) has secured a U.S. patent for manufacturing methods of double-stranded RNA, including Ampligen®, extending protection until 2041. The company’s CEO, Equels Thomas K, demonstrates confidence in AIM by purchasing additional shares, despite the company’s current financial challenges. AIM faces significant financial hurdles, with a negative price-to-earnings (P/E) ratio of -0.44 and a current ratio of 0.26, indicating potential liquidity issues.

Read more at Financial Modeling Prep:: AIM ImmunoTech Inc. (AMEX:AIM) Strengthens Intelle…